metreleptin

01/01/2019 - "Subgroup analysis of a prospective open-label study of metreleptin in lipodystrophy. "
05/01/2015 - "This study extends knowledge about metreleptin replacement in genetic lipodystrophies, bearing out its effectiveness for long periods of time."
07/29/2023 - "Single-arm prospective study of metreleptin administration in 15 patients with lipodystrophy, nine of whom had data on GNG. "
07/03/2023 - "Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy."
01/01/2022 - "To describe baseline characteristics and follow-up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network, in a real-life setting. "

12/14/2018 - "This entity is associated with diabetes with prominent insulin resistance and severe hypertriglycemia and can be successfully treated with metreleptin for the long term."
01/01/2018 - "After only 1 year, treatment with metreleptin reestablishes brain insulin sensitivity, particularly in the hypothalamus and, to a lesser degree, in the prefrontal cortex. "
01/01/2018 - "With food intake constant, peripheral insulin sensitivity decreased by 41% after stopping metreleptin for 14 days (withdrawal cohort) and increased by 32% after treatment with metreleptin for 14 days (initiation cohort). "
01/01/2021 - "Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance."
01/01/2019 - "Children with extreme insulin resistance had a high prevalence of thyroid nodules, which were not associated with metreleptin treatment. "

01/01/2018 - "The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy. "
01/01/2015 - "Following many successful trials, the US Food and Drug Administration approved metreleptin for the treatment of non-HIV-related forms of generalized lipodystrophy. "
01/01/2023 - "Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year"
07/26/2022 - "Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution."
09/01/2020 - "Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy."

01/01/2023 - "Treatment with metreleptin may prove beneficial in AN and in ME/CSF associated with substantial weight loss."
01/01/2013 - "The only systemic treatment is the substitution with metreleptin leading to weight reduction based on hormonal changes. "
09/01/2011 - "Eleven were randomized to metreleptin (initial dose, 0.08 mg/[kg·d] for 3 months; altered thereafter to 0.12 mg/kg for lack of efficacy or 0.04 mg/[kg d] for more than 5% weight loss) and 9 were randomized to placebo for 9 months. "
01/01/2023 - "A 17 years-old male adolescent with possible onset of ME/CFS after an Epstein Barr Virus infection (EBV) and later onset of AN during a second period of weight loss was twice treated off-label with metreleptin for 15 and 11 days, respectively. "
09/01/2009 - "Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9%; least squares mean +/- s.e.) than treatment with pramlintide (-8.4 +/- 0.9%; P < 0.001) or metreleptin (-8.2 +/- 1.3%; P < 0.01) alone (evaluable, N = 93). "

01/01/2019 - "In contrast, metreleptin had little effect in patients with multifactorial obesity. "
07/01/2015 - "Metreleptin, in conjunction with other pharmacologic interventions, has the potential to address one of the most widespread epidemics of our time, obesity. "
01/01/2016 - "Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy."
12/01/2015 - "These findings provide a potential mechanism for the increased efficacy of a metreleptin/pramlintide combination therapy for obesity. "
09/01/2009 - "These results support further development of pramlintide/metreleptin as a novel, integrated neurohormonal approach to obesity pharmacotherapy."